Novo Nordisk A/S EBIT

The latest EBIT for NOV.DE is $140B as of June 2026. That compares with $150B in the prior-year period — down 2.1% year over year. That is above the Healthcare sector average of $22B. Investors often review this figure alongside Novo Nordisk A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, NOV.DE's EBIT moved from $150B to $140B — a 2.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novo Nordisk A/S's operating scale or balance-sheet position.

Against Healthcare companies, NOV.DE currently prints $140B for EBIT, while the sector average sits near $22B. That is roughly 540.9% above the sector mean. Large gaps often invite a closer look at Novo Nordisk A/S's growth, margins, and balance sheet.

A EBIT figure of $140B for NOV.DE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting NOV.DE's EBIT ($140B), review year-over-year change from $150B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.